MX339840B - Moduladores de los receptores de 5-ht y metodos de uso de los mismos. - Google Patents

Moduladores de los receptores de 5-ht y metodos de uso de los mismos.

Info

Publication number
MX339840B
MX339840B MX2012013536A MX2012013536A MX339840B MX 339840 B MX339840 B MX 339840B MX 2012013536 A MX2012013536 A MX 2012013536A MX 2012013536 A MX2012013536 A MX 2012013536A MX 339840 B MX339840 B MX 339840B
Authority
MX
Mexico
Prior art keywords
methods
compounds
modulators
receptors
compositions
Prior art date
Application number
MX2012013536A
Other languages
English (en)
Other versions
MX2012013536A (es
Inventor
C Turner Sean
F Gasiecki Alan
Braje Wilfried
Zhang Min
W Djuric Stevan
Gandarilla Jorge
Shekhar Shashank
Relo Ana-Lucia
S Welch Dennie
W Kruger Albert
Zhao Hongyu
Li Huanqiu
M Thompson Christina
Akritopoulou-Zanze Irini
s wilson Noel
Original Assignee
Abbvie Inc *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/784,624 external-priority patent/US9187483B2/en
Application filed by Abbvie Inc * filed Critical Abbvie Inc *
Publication of MX2012013536A publication Critical patent/MX2012013536A/es
Publication of MX339840B publication Critical patent/MX339840B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)

Abstract

La presente solicitud se refiere a derivados de decahidropirroloazepina, octahidro-oxepinopirrol, dióxido de octahidropirrolotiazepina, decahidrociclohepta[c]pirrol fusionados a arilo y heteroarilo, y derivados de octahidrociclohepta[c]pirrol de la fórmula (I) en la cual R1, R2, R3, R4, R5, A, Y1, Y2, y Y3 son como se definen en la descripción. La presente solicitud también se refiere a composiciones que comprenden dichos compuestos, a procedimientos para elaborar dichos compuestos, y a métodos para tratar condiciones patológicas utilizando dichos compuestos y composiciones, y a métodos para identificar dichos compuestos.
MX2012013536A 2010-05-21 2010-11-19 Moduladores de los receptores de 5-ht y metodos de uso de los mismos. MX339840B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/784,624 US9187483B2 (en) 2009-05-22 2010-05-21 Modulators of 5-HT receptors and methods of use thereof
PCT/US2010/057454 WO2011146089A1 (en) 2010-05-21 2010-11-19 Modulators of 5-ht receptors and methods of use thereof
US12/950,029 US8846951B2 (en) 2009-05-22 2010-11-19 Modulators of 5-HT receptors and methods of use thereof

Publications (2)

Publication Number Publication Date
MX2012013536A MX2012013536A (es) 2013-06-28
MX339840B true MX339840B (es) 2016-06-14

Family

ID=44991967

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012013536A MX339840B (es) 2010-05-21 2010-11-19 Moduladores de los receptores de 5-ht y metodos de uso de los mismos.

Country Status (14)

Country Link
US (1) US8846951B2 (es)
EP (1) EP2571353B1 (es)
JP (1) JP5996528B2 (es)
KR (1) KR101770979B1 (es)
CN (2) CN103002735B (es)
AU (1) AU2010353724B2 (es)
BR (1) BR112012030534A2 (es)
CA (1) CA2800161C (es)
IL (1) IL223392A (es)
MX (1) MX339840B (es)
NZ (1) NZ603792A (es)
RU (2) RU2015140748A (es)
SG (1) SG185672A1 (es)
WO (1) WO2011146089A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011116282A2 (en) 2010-03-19 2011-09-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nicotinic acetylcholine receptor agonists
WO2013187069A1 (ja) * 2012-06-15 2013-12-19 国立大学法人金沢大学 Ｐｄｔ効果増強剤
CN102796044A (zh) * 2012-08-24 2012-11-28 南通大学 2,3,4,5-四氢-1h-2-苯并氮杂卓-1-酮衍生物的化学合成方法
US9643947B2 (en) 2013-08-28 2017-05-09 Northwestern University 7-membered fused heterocycles and methods of their synthesis
CN110167560B (zh) 2016-08-30 2023-08-18 四相制药公司 四环素化合物和治疗方法
CA3054782A1 (en) 2017-03-13 2018-09-20 Sumitomo Dainippon Pharma Co., Ltd. 2,6-disubstituted pyridine derivative
IL271149B2 (en) * 2017-06-14 2024-05-01 Trevena Inc Compounds for modulating s1p1 activity and methods of using the same
JP2023502123A (ja) 2019-11-19 2023-01-20 トレベナ・インコーポレイテッド Ｓ１ｐ１モジュレーター化合物及び化合物を調製する方法
CN111423410B (zh) * 2020-05-11 2022-11-15 无锡贝塔医药科技有限公司 一种稳定性同位素13c标记1,4-二硫-2，5-二醇的合成方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4268513A (en) * 1979-10-22 1981-05-19 Ici Americas Inc. Pyrrolo [3,4-c]quinoline compounds and pharmaceutical compositions, methods for their use and preparation
US4350814A (en) * 1979-10-22 1982-09-21 Ici Americas Inc. Pyrrolo [3,4-c]quinoline compounds
US4440768A (en) * 1981-01-08 1984-04-03 Ici Americas Inc. Hexahydropyrrolo[3,4-c]quinoline compounds and pharmaceutical compositions, and methods for their use
US5049564A (en) * 1989-11-17 1991-09-17 Abbott Laboratories 5-HT selective agents
JPH03502701A (ja) 1988-12-15 1991-06-20 アボツト・ラボラトリーズ ５‐ｈｔ選択性物質
US5387590A (en) 1989-08-30 1995-02-07 Pfizer Inc. Benzazabicyclic carbamates as novel cholinesterase inhibitors
DK0656001T3 (da) * 1992-08-24 2000-04-03 Merrell Pharma Inc Nye 2-substituerede indan-2-mercaptoacetylamid-tricycliske derivater til anvendelse som enkefalinasehæmmere
US5317017A (en) * 1992-09-30 1994-05-31 Merck & Co., Inc. N-biphenyl-3-amido substituted benzolactams stimulate growth hormone release
US5597922A (en) * 1994-07-29 1997-01-28 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Glycine receptor antagonist pharmacophore
WO1996038435A1 (en) 1995-05-30 1996-12-05 Abbott Laboratories Dopamine agonists
JPH09221475A (ja) 1996-02-13 1997-08-26 Yamanouchi Pharmaceut Co Ltd 新規なオキシム誘導体
US5880122A (en) * 1996-11-01 1999-03-09 American Home Products Corporation 3-Carboxamide derivatives of 5H-pyrrolo 2,1-c! 1,4!-benzodiazepines
WO1999040093A2 (en) 1998-02-04 1999-08-12 Board Of Regents, The University Of Texas System Synthesis of quinobenzoxazine analogues with topoisomerase ii and quadruplex interactions for use as antineoplastic agents
EP1244457B1 (en) 1999-12-29 2004-10-27 Glaxo Group Limited Use of modulators of annexin for the manufacture of a medicament for the treatment and/or prevention of arthritis and arthritic diseases
CA2450315A1 (en) 2001-06-13 2002-12-19 The Regents Of The University Of Michigan Dopamine receptor ligands and therapeutic methods based thereon
US20080146583A1 (en) * 2003-05-15 2008-06-19 Pfizer Inc Treatment of Incontinence
AU2004259009A1 (en) 2003-07-23 2005-02-03 Exelixis, Inc. Azepine derivatives as pharmaceutical agents
KR100601641B1 (ko) * 2003-08-08 2006-07-14 삼성전자주식회사 비피리딘계 금속 착화합물 및 이를 포함하는 잉크 조성물
RU2266906C1 (ru) 2004-04-29 2005-12-27 Общество с ограниченной ответственностью "Исследовательский Институт Химического Разнообразия" (ООО "Исследовательский Институт Химического Разнообразия") Анелированные карбамоилазагетероциклы, способы их получения (варианты), фармацевтическая композиция, фокусированная библиотека
EP1778243B1 (en) * 2004-06-30 2012-10-31 Athersys, Inc. Substituted azepine derivatives as serotonin receptor modulators
US7618980B2 (en) * 2004-07-14 2009-11-17 Bristol-Myers Squibb Company Pyrrolo(oxo)quinolines as 5HT ligands
US7572805B2 (en) * 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
TW200621677A (en) * 2004-09-21 2006-07-01 Astellas Pharma Inc Cyclic amine derivative or salt thereof
ES2332526T3 (es) * 2004-12-21 2010-02-08 F. Hoffmann-La Roche Ag Derivados de tetralina e indano y usos de los mismos.
AU2005318596B2 (en) * 2004-12-21 2010-12-23 F. Hoffmann-La Roche Ag Chroman derivatives and their use as 5-HT receptor ligands
KR20130087622A (ko) * 2004-12-23 2013-08-06 아레나 파마슈티칼스, 인크. 5ｈｔ２ｃ 수용체 조정물질 조성물 및 그의 사용 방법
JP2009501705A (ja) * 2005-07-05 2009-01-22 アストラゼネカ・アクチエボラーグ 新規化合物、その製造方法、中間体、医薬組成物、並びにアルツハイマー病、認知障害、統合失調症に伴う認識機能障害、肥満及びパーキンソン病のような５−ｈｔ６介在疾患の治療におけるそれらの使用
CA2614385A1 (en) * 2005-07-12 2007-01-18 Abbott Gmbh & Co. Kg Pyridazine compounds as glycogen synthase kinase 3 inhibitors
ATE529430T1 (de) * 2005-07-28 2011-11-15 Vertex Pharma Caspase-hemmer-propharmaka
EP1928461B1 (en) * 2005-08-04 2012-01-04 Janssen Pharmaceutica NV Pyrimidine compounds as serotonin receptor modulators
GB0517292D0 (en) 2005-08-24 2005-10-05 Univ Dundee Cell migration modulating compounds
WO2007025880A2 (en) * 2005-08-31 2007-03-08 F. Hoffmann-La Roche Ag Pyrazolone derivatives as 11-beta hsd1 inhibitors
AU2006308655B2 (en) 2005-11-01 2010-09-23 The Regents Of The University Of Michigan Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
JP5237108B2 (ja) 2005-12-08 2013-07-17 アボット・ラボラトリーズ タンパク質キナーゼ阻害薬としての９員ヘテロ二環式化合物
PE20081192A1 (es) * 2006-03-24 2008-10-07 Wyeth Corp Tratamiento del dolor
KR20080107430A (ko) * 2006-03-24 2008-12-10 와이어쓰 방광 기능 조절 방법
EP2114948B1 (en) * 2006-12-28 2014-06-25 AbbVie Inc. Inhibitors of poly(adp-ribose)polymerase
TW200924752A (en) 2007-09-17 2009-06-16 Organon Nv Tricyclic heterocyclic derivatives
ES2416062T3 (es) 2008-03-27 2013-07-30 Bristol-Myers Squibb Company Inhibidores de NS5B del VHC de indolobenzadiazepina condensados con pirrolidina
GB0817576D0 (en) 2008-09-25 2008-11-05 Lectus Therapeutics Ltd Calcium ion channel modulators & uses thereof
RU2014147175A (ru) * 2009-05-22 2015-06-27 Эббви Инк. Модуляторы рецепторов 5-нт и способы их применения

Also Published As

Publication number Publication date
CA2800161A1 (en) 2011-11-24
AU2010353724B2 (en) 2015-02-12
US8846951B2 (en) 2014-09-30
KR101770979B1 (ko) 2017-08-24
CN104860951A (zh) 2015-08-26
CN103002735B (zh) 2015-05-20
WO2011146089A1 (en) 2011-11-24
EP2571353A4 (en) 2014-01-22
AU2010353724A1 (en) 2012-12-20
RU2567751C2 (ru) 2015-11-10
RU2015140748A (ru) 2018-12-26
MX2012013536A (es) 2013-06-28
CA2800161C (en) 2017-12-12
SG185672A1 (en) 2013-01-30
US20110118231A1 (en) 2011-05-19
JP5996528B2 (ja) 2016-09-21
IL223392A (en) 2017-01-31
CN103002735A (zh) 2013-03-27
RU2012155694A (ru) 2014-06-27
JP2013526618A (ja) 2013-06-24
EP2571353A1 (en) 2013-03-27
NZ603792A (en) 2015-07-31
EP2571353B1 (en) 2017-08-09
KR20130097089A (ko) 2013-09-02
BR112012030534A2 (pt) 2015-09-29

Similar Documents

Publication Publication Date Title
MX339840B (es) Moduladores de los receptores de 5-ht y metodos de uso de los mismos.
WO2010003133A3 (en) Cdk modulators
MX2011009369A (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2009011205A (es) Derivados de 2-iminoisotiazol como ligandos del receptor canabinoide.
EA201100666A1 (ru) Тиоамидные соединения, способ их получения и способ их применения
MX2009012082A (es) Compuestos de ariloazol-2-il cianoetilamino, metodo para prepararlos y metodo para utilizarlos.
MX2011008864A (es) Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales.
MY163216A (en) Compositions and methods for modulating fxr
MX2011012479A (es) Moduladores de los receptores 5-ht y metodos de uso de los mismos.
MY153057A (en) Tryclic compounds,compositions and methods
TW200738631A (en) Indole sulfonamide modulators of progesterone receptors
EA201070605A1 (ru) Применение бактерий для производства биоэнергии
MX2013012211A (es) Derivados biciclicos substituidos de metil amina como moduladores de receptores de esfingosina-1-fosfato.
MX2009001494A (es) 2-aminobenzoxazol carboxamidas como moduladores 5ht3.
MY154962A (en) Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a seratonin receptor
MX2011008825A (es) 3-aminoisoxazolopiridinas sustituidas como moduladores de kcnq2/3.
IN2012DN05125A (es)
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
MX2009012374A (es) Compuestos novedosos como ligandos del receptor de canabinoides.
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
CA2818986A1 (en) Indole derivatives as modulators of s1p receptors
EA200900090A1 (ru) Бензиламины, способ их получения и их применение в качестве противовоспалительных средств
MX2011008662A (es) 2-mercapto-3-aminopiridinas sustituidas como moduladores de kcnq2/3.
MX2011009338A (es) 3-amino-2-mercaptoquinolinas sustituidas como moduladores de kcnq2/3.
MX2012007896A (es) Derivados de piridino-piridinonas arilsulfonamidas, su preparacion y su uso en terapeutica.

Legal Events

Date Code Title Description
GB Transfer or assignment

Owner name: ABBVIE INC.*

FG Grant or registration